Higher Neurofilament Light Chain Levels Seen Before MS Disability Worsening
By Lori Solomon HealthDay Reporter
THURSDAY, Nov. 16, 2023 -- Pronounced neuroaxonal damage precedes disability worsening events with or without preceding clinical relapses in people with multiple sclerosis (MS), according to a study published online Nov. 6 in JAMA Neurology.
Ahmed Abdelhak, M.D., from University of California at San Francisco, and colleagues assessed whether and when neurofilament light chain (NfL) levels are elevated in the context of confirmed disability worsening (CDW) with MS. The analysis included data from two observational cohorts seen at tertiary MS centers (609 and 1,290 participants).
The researchers found that NfL z scores were 0.71 units higher in the first cohort and 0.32 higher in the second cohort for CDW associated with clinical relapse versus stable MS. Higher NfL was detected preceding CDW independent of clinical relapse for two visits preceding the event and for the visit directly preceding the event. Findings were similar for the subset of individuals with relapsing-remitting MS.
"This cohort study documents the occurrence of NfL elevation in advance of clinical worsening and may hint to a potential window of ongoing dynamic central nervous system pathology that precedes the diagnosis of CDW," the authors write.
Several authors disclosed ties to industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
High-Efficacy Therapy Cuts Disability Progression in Pediatric MS
FRIDAY, April 12, 2024 -- Treatment of pediatric-onset relapsing-remitting multiple sclerosis with high-efficacy therapy reduces the risk for transition across disability states...
AAN: Monoclonal Antibodies for MS During Breastfeeding Not Harmful
TUESDAY, March 12, 2024 -- For mothers with multiple sclerosis or neuromyelitis optica spectrum disease, receipt of monoclonal antibodies (mAb) during breastfeeding is not...
Frexalimab Has Favorable Effect on Relapsing Multiple Sclerosis
WEDNESDAY, Feb. 14, 2024 -- For patients with relapsing multiple sclerosis, the anti-CD40L monoclonal antibody frexalimab has a favorable effect on the number of new...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.